Renalytix Plc (NASDAQ:RNLX) Sees Significant Decline in Short Interest

Renalytix Plc (NASDAQ:RNLX) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totalling 236,600 shares, a decline of 49.1% from the May 31st total of 464,900 shares. Based on an average daily trading volume, of 267,400 shares, the short-interest ratio is currently 0.9 days.

Renalytix Price Performance

Shares of RNLX stock traded down $0.03 during trading hours on Friday, reaching $0.23. 863,451 shares of the company traded hands, compared to its average volume of 1,133,304. Renalytix has a 12-month low of $0.22 and a 12-month high of $4.04. The company has a market cap of $17.83 million, a P/E ratio of -0.59 and a beta of 2.88. The firm has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.61.

Renalytix (NASDAQ:RNLX) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.08) EPS for the quarter. Renalytix had a negative return on equity of 1,008.88% and a negative net margin of 1,687.80%. The business had revenue of $0.54 million during the quarter. Sell-side analysts predict that Renalytix will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Renalytix stock. Pinnacle Associates Ltd. raised its position in shares of Renalytix Plc (NASDAQ:RNLX) by 7.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 846,534 shares of the company’s stock after acquiring an additional 60,572 shares during the period. Pinnacle Associates Ltd. owned approximately 1.69% of Renalytix worth $330,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 9.92% of the stock is owned by institutional investors and hedge funds.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.